Jump to content

Immuron

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 202.134.37.240 (talk) at 04:39, 27 March 2018 (Updated information added to include the name change from Anadis to Immuron Ltd - https://www.asx.com.au/prices/company-name-and-asx-code-changes-2008.htm). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Anadis is a biotechnology company based in Melbourne, Australia.[1] In 2008 Anadis changed its name to Immuron Ltd.

The company focused on antigen-primed, dairy-derived health products. Immuron’ proprietary, technology enables it to rapidly develop polyclonal antibody and other proteins-based solutions to a range of important diseases.[citation needed]

Immuron specialises in nutraceutical, pharmaceutical and related therapeutic technology products, including Oral and GI Mucositis, Routine and Avian Influenza, - E. coli Travellers' diarrhoea (TD), Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), and Anthrax containment.

In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for distribution of Travelan, a product by Anadis, in Canadian market.[2]

References

  1. ^ "Anadis". Australian Stock Exchange. 5 June 2007.[permanent dead link]
  2. ^ Canada, Asia Pacific Foundation of. "Valeo Pharma, Baralex Sign Distribution Agreement with Australia's Anadis Ltd". Asia Pacific Foundation of Canada. Retrieved 18 September 2017.


Stub icon

This biotechnology article is a stub. You can help Wikipedia by expanding it.

Stub icon

This pharmacy-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Immuron&oldid=832637986"